Search

Author/Creator McKee, Amy

2. FDA Benefit‐Risk Assessment of Osimertinib for the Treatment of Metastatic Non‐Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation. (14th December 2017)

Authors:
Odogwu, Lauretta; Mathieu, Luckson; Goldberg, Kirsten B.; Blumenthal, Gideon M.; Larkins, Erin; Fiero, Mallorie H.; Rodriguez, Lisa; Bijwaard, Karen; Lee, Eunice Y.; Philip, Reena; Fan, Ingrid; Donoghue, Martha; Keegan, Patricia; McKee, Amy; Pazdur, Richard
Journal:
Oncologist
Issue:
Volume 23:Number 3(2018)
Page Start:
353
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗